C Sotiriou

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. ncbi Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
  2. doi No significant viral transcription detected in whole breast cancer transcriptomes
    Danai Fimereli
    IRIBHM Université Libre de Bruxelles, ULB, Campus Erasme CP602, 808 Route de Lennik, 1070, Brussels, Belgium
    BMC Cancer 15:1176. 2015
  3. pmc Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory BCTL, Institut Jules Bordet, Brussels, Belgium
    BMC Genomics 15:1008. 2014
  4. pmc Decoding the evolution of a breast cancer genome
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    EMBO Mol Med 2:3-5. 2010
  5. pmc Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis
    Hatem A Azim
    Breast Cancer Translational Research Laboratory, JC Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e62451. 2013
  6. pmc Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e66848. 2013
  7. pmc Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer
    Françoise Rothé
    Translational Research Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 6:e20980. 2011
  8. pmc Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS)
    Jérôme Toussaint
    Breast Cancer Translational Research Laboratory JC Heuson, Jules Bordet Institute, Brussels, Belgium
    PLoS ONE 5:. 2010
  9. pmc Multiple-input multiple-output causal strategies for gene selection
    Gianluca Bontempi
    Machine Learning Group, Computer Science Department, Universite Libre de Bruxelles, Belgium
    BMC Bioinformatics 12:458. 2011
  10. pmc Loss, mutation and deregulation of L3MBTL4 in breast cancers
    Lynda Addou-Klouche
    Marseille Cancer Research Center, Department of Molecular Oncology, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Mol Cancer 9:213. 2010

Detail Information

Publications112 found, 100 shown here

  1. ncbi Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
    ..A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients...
  2. doi No significant viral transcription detected in whole breast cancer transcriptomes
    Danai Fimereli
    IRIBHM Université Libre de Bruxelles, ULB, Campus Erasme CP602, 808 Route de Lennik, 1070, Brussels, Belgium
    BMC Cancer 15:1176. 2015
    ..Studies evaluating the presence of viral sequences in breast cancer (BC), including various strains of human papillomavirus and human herpes virus, have yielded conflicting results. Most were based on RT-PCR and in situ hybridization...
  3. pmc Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory BCTL, Institut Jules Bordet, Brussels, Belgium
    BMC Genomics 15:1008. 2014
    ..0 chips and sequenced using the Illumina HiSeq 2000 platform. The correlations of three clinically relevant BC genes, six molecular subtype classifiers, and a selection of 21 GES were evaluated...
  4. pmc Decoding the evolution of a breast cancer genome
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    EMBO Mol Med 2:3-5. 2010
    ..Philippe Bedard and Christos Sotiriou analyse their findings as well as the challenges of applying the study of cancer genomes to clinical cancer care...
  5. pmc Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis
    Hatem A Azim
    Breast Cancer Translational Research Laboratory, JC Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e62451. 2013
    ..SPARC is an important regulator of the extracellular matrix and has been suggested to improve delivery of albumin-bound cytotoxics. However, little is known regarding its role in breast cancer (BC)...
  6. pmc Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e66848. 2013
    ..In this prospective study we sought to evaluate the feasibility of performing GGI in routine clinical practice and its impact on treatment recommendations...
  7. pmc Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer
    Françoise Rothé
    Translational Research Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 6:e20980. 2011
    ..In this study, we investigated miRNA profiling as a complementary tool to improve our understanding of breast cancer (BC) biology and to assess whether miRNA expression could predict clinical outcome of BC patients...
  8. pmc Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS)
    Jérôme Toussaint
    Breast Cancer Translational Research Laboratory JC Heuson, Jules Bordet Institute, Brussels, Belgium
    PLoS ONE 5:. 2010
    ..The aim of our study was to retrospectively evaluate the prognostic value of CD10 in DCIS...
  9. pmc Multiple-input multiple-output causal strategies for gene selection
    Gianluca Bontempi
    Machine Learning Group, Computer Science Department, Universite Libre de Bruxelles, Belgium
    BMC Bioinformatics 12:458. 2011
    ..In this study, we show how to efficiently incorporate causal information into gene selection by moving from a single-input single-output to a multiple-input multiple-output setting...
  10. pmc Loss, mutation and deregulation of L3MBTL4 in breast cancers
    Lynda Addou-Klouche
    Marseille Cancer Research Center, Department of Molecular Oncology, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Mol Cancer 9:213. 2010
    ..Many alterations are involved in mammary oncogenesis, including amplifications of oncogenes and losses of tumor suppressor genes (TSG). Losses may affect almost all chromosome arms and many TSGs remain to be identified...
  11. pmc A fuzzy gene expression-based computational approach improves breast cancer prognostication
    Benjamin Haibe-Kains
    Functional Genomics and Translational Research Unit, Medical Oncology Department, Jules Bordet Institute, boulevard de Waterloo, Brussels, 1000, Belgium
    Genome Biol 11:R18. 2010
    ..In systematic evaluations, GENIUS significantly outperformed current gene signatures and clinical indices in the global population of patients...
  12. pmc Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
    ....
  13. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
    ..When treated with adjuvant tamoxifen, those ER+ BCs that are lowly proliferative have a good prognosis (luminal-A subtype), however the clinical outcome of those that are highly proliferative is poor (luminal-B subtype)...
  14. pmc Comparison of prognostic gene expression signatures for breast cancer
    Benjamin Haibe-Kains
    Functional Genomics Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Genomics 9:394. 2008
    ..However, signatures were never compared on an independent population of untreated breast cancer patients, where risk assessment was computed using the original algorithms and microarray platforms...
  15. pmc Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
    Jérôme Toussaint
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 10:424. 2009
    ....
  16. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
    ..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings...
  17. pmc Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
    Qiyuan Li
    Center for Biological Sequence Analysis, Department of Systems Biolology, Technical University of Denmark, 2800 Lyngby, Denmark
    BMC Bioinformatics 12:310. 2011
    ..However, identification of clinically predictive or prognostic classifiers can be challenging when a large number of genes are measured in a small number of tumors...
  18. ncbi Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  19. pmc Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer
    Christos Sotiriou
    Division of Clinical Sciences, Advanced Technology Center, National Cancer Institute, National Institutes of Health, Gaithersburg, USA
    Breast Cancer Res 4:R3. 2002
    ..Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response...
  20. ncbi Molecular profiling of head and neck tumors
    C Sotiriou
    Translational Unit, Jules Bordet Institute, Brussels, Belgium
    Curr Opin Oncol 16:211-4. 2004
    ..This article reviews recently reported studies that have used such approaches...
  21. pmc The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Med Genomics 2:40. 2009
    ..Here, we aim to investigate the ability of the GGI to predict relapses in postmenopausal women who were treated with tamoxifen (T) or letrozole (L) within the BIG 1-98 trial...
  22. doi Gene profiling assay and application: the predictive role in primary therapy
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Bruxelles 1000, Belgium
    J Natl Cancer Inst Monogr 2011:124-7. 2011
    ....
  23. ncbi Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer
    V Durbecq
    Translational Research Unit, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Int J Oncol 25:1473-9. 2004
    ..Although the great majority of topo-II gene aberrations occur in HER-2 positive tumors, the level of HER-2 amplification does not predict for topo-II amplification...
  24. ncbi Investigating the predictive value of topoisomerase II alpha (TOP2A) gene, mRNA and protein levels in anthracycline-treated estrogen receptor (ER) negative breast cancer (BC) patients
    C Desmedt
    Jules Bordet Institute, Brussels, Belgium Institut Gustave Roussy, Villejuif, France Ccentre Hospitalier du Lxembourg, Luxembourg, Luxembourg Hospital of Prato, Prato, Italy
    J Clin Oncol 26:11065. 2008
    ....
  25. pmc Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
    E de Azambuja
    Medical Oncology Clinic, Jules Bordet Institute, 125 Boulevard de Waterloo, 1000, Brussels, Belgium
    Br J Cancer 96:1504-13. 2007
    ..65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC...
  26. ncbi Use of genomic grade index to improve tumor grading of invasive lobular breast carcinoma
    D Fumagalli
    Jules Bordet Institute, Brussels, Belgium Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Institut Jules Bordet, Brussels, Belgium Ipsogen, Marseille, France Cliniques Universitaires Saint Luc, Brussels, Belgium Institut Paoli Calmettes, Marseille, France
    J Clin Oncol 29:535. 2011
    ..It is particularly useful in segregating HG2 tumors into low and high genomic grade (GG1 and GG3). In the current study we evaluated the ability of GGI to grade ILC, and hypothesized that GGI would have prognostic value in ILC...
  27. ncbi Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172)
    E de Azambuja
    Jules Bordet Institute, Brussels, Belgium Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Hospital Santa Rita, Sao Paulo, Brazil European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium Institut Jules Bordet, Brussels, Belgium Champalimaud Cancer Center, Lisbon, Portugal GlaxoSmithKline, Brussels, Belgium
    J Clin Oncol 29:570. 2011
    ..This study was designed to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of L + T in pts with BM from HER2+ metastatic breast cancer...
  28. ncbi Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers
    Amir A Jazaeri
    Laboratory of Biosystems and Cancer, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:6300-10. 2005
    ..The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in epithelial ovarian carcinoma...
  29. ncbi Correlation of gene expression analysis of tumor-infiltrating CD4+ cells with immune function and survival according to different breast cancer (BC) molecular subtypes
    C Sotiriou
    Jules Bordet Institute, Brussels, Belgium
    J Clin Oncol 26:11022. 2008
    ..However, its role in BC remains largely unknown. Here, we aim to gain further insight into the functional defects characterizing breast tumor-infiltrating T cells and to assess their relationship with BC subtypes and clinical outcome...
  30. doi Genomic grade adds prognostic value in invasive lobular carcinoma
    O Metzger-Filho
    Breast Cancer Translation Research Laboratory J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:377-84. 2013
    ..Genomic grade (GG) is a 97-gene signature that improves the prognostic value of HG. This study evaluates whether GG may overcome the limitations of HG in ILC...
  31. doi A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics
    V Durbecq
    Translational Research Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Crit Rev Oncol Hematol 67:80-92. 2008
    ....
  32. doi Aiming at the target: improved adjuvant medical therapy
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Rue Heger Bordet 1, Brussels, Belgium
    Breast 18:S25-30. 2009
    ..It is hoped that coupling prospective biomarker discovery with new drug development in earlier stages of disease will yield additional targets that can be used to guide clinical decision-making in the future...
  33. ncbi Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial
    C Desmedt
    Jules Bordet Institute, Brussels, Belgium Hospital of Prato, Prato, Italy Institut Gustave Roussy, Villejuif, France Centre Hospitalier de Luxembourg, Luxembourg
    J Clin Oncol 27:523. 2009
    ....
  34. ncbi Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling
    H A Azim
    Jules Bordet Institute, Brussels, Belgium Department of Medical Oncology, Princess Margaret and University of Toronto, Toronto, ON, Canada Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 29:10603. 2011
    ..Whether the performance of prognostic gene expression signatures (GS) varies by BC subtype across age groups is unknown...
  35. ncbi Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes
    M Lacroix
    Laboratoire Jean Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Free University of Brussels, Brussels, Belgium
    Oncol Rep 12:701-7. 2004
    ....
  36. pmc A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?
    B Haibe-Kains
    Machine Learning Group, Department of Computer Science, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Bioinformatics 24:2200-8. 2008
    ..The aim of this work is to assess quantitatively the accuracy of prediction obtained with state-of-the-art data analysis techniques for BC microarray data through an independent and thorough framework...
  37. ncbi Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    Virginie Durbecq
    Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
    Mol Cancer Ther 3:1207-14. 2004
    ..The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel...
  38. ncbi What clinicians need to know about antioestrogen resistance in breast cancer therapy
    Amalia Milano
    Medical Oncology and Translational Research Unit, Jules Bordet Institute, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
    Eur J Cancer 42:2692-705. 2006
    ..Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed...
  39. ncbi The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
    Sherene Loi
    Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Crit Rev Oncol Hematol 61:187-94. 2007
    ....
  40. ncbi CD10 expression and risk of relapse in DCIS
    J Toussaint
    Jules Bordet Institute, Brussels, Belgium Antwerp University Hospital, Edegem, Belgium
    J Clin Oncol 27:e22053. 2009
    ..The aim of the present study was to retrospectively evaluate the prognostic value of CD10 in DCIS...
  41. pmc The AURORA initiative for metastatic breast cancer
    D Zardavas
    1 Breast International Group Headquarters BIG aisbl, Brussels, Belgium 2 Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Br J Cancer 111:1881-7. 2014
    ..AURORA, through its innovative design, will shed light onto some of the unknown areas of metastatic breast cancer, helping to improve the clinical outcome of breast cancer patients. ..
  42. doi Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
    S Loi
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne, Australia
    Ann Oncol 25:1544-50. 2014
    ..In this study, we aimed to validate these findings and also investigate associations with trastuzumab benefit in HER2-overexpressing disease (HER2+)...
  43. ncbi Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases
    C Sotiriou
    Laboratory of Endocrinology/Bone Metabolism and Breast Cancer Research, Institut Jules Bordet, boulevard de Waterloo, 127B-1000, Brussels, Belgium
    Cancer Lett 169:87-95. 2001
    ..Our findings demonstrate for the first time IL-11 gene expression in some primary invasive breast tumors and suggest the potential of this cytokine as possible biological predictive factor for the development of bone metastases...
  44. ncbi New data on chemotherapy in the adjuvant setting
    M J Piccart
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Breast 12:373-8. 2003
    ..The 3-year results of this trial strongly support concept 1; a longer follow-up and a confirmation study are desirable before recommending changes in routine patient care...
  45. doi Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH
    Christine Desmedt
    Department of Medical Oncology, Jules Bordet Institute, Brussels
    Diagn Mol Pathol 18:22-9. 2009
    ..27 (HER2:HER2 dimers)]. These data suggest that more quantitative or functional measurements of HER2 status may facilitate the development of more personalized treatment strategies for patients with metastatic breast cancer...
  46. ncbi Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers
    Amir A Jazaeri
    Division of Clinical Sciences of the National Cancer Institute, Gaithersburg, MD, USA
    J Natl Cancer Inst 94:990-1000. 2002
    ....
  47. ncbi Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer
    W F Symmans
    University of Texas M D Anderson Cancer Center, Houston, TX Nuvera Biosciences Inc, Woburn, MA Institut Jules Bordet, Brussels, Belgium
    J Clin Oncol 26:541. 2008
    ..In the current study we examined whether GGI predicts pathologic response to neoadjuvant chemotherapy in 229 patients with HER2-normal breast cancer. We hypothesized that high GGI will predict for greater sensitivity to chemotherapy...
  48. doi Pertuzumab: new hope for patients with HER2-positive breast cancer
    M Capelan
    Department of Medicine, Institute Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:273-82. 2013
    ..Pertuzumab is a new anti-HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers...
  49. doi Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer
    M J Piccart-Gebhart
    Department of Medicine, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 18:xii2-7. 2007
    ..Close collaboration between clinicians and scientists will be essential to achieve this goal...
  50. doi Treatment tailoring based on molecular characterizations
    P Dinh
    Medical Oncology Department, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Belgium
    Ann Oncol 19:vii46-50. 2008
  51. doi Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer
    Carolyn Straehle
    Breast International Group, Brussels, Belgium
    Crit Care Med 37:S22-9. 2009
    ....
  52. pmc PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    Proc Natl Acad Sci U S A 107:10208-13. 2010
    ..In ER+ BC cell lines, PIK3CA mutations were also associated with sensitivity to tamoxifen. These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors...
  53. pmc HER2-positive circulating tumor cells in breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    PLoS ONE 6:e15624. 2011
    ..Tumor cell dissemination has been suggested to occur early in BC progression. To interrogate dissemination in BC, we studied CTCs and HER2 expression on CTCs across the spectrum of BC staging...
  54. doi Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients
    Fabrice Journe
    Laboratory of Endocrinology and Translational Research Unit, Department of Internal Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Breast Cancer Res Treat 115:523-35. 2009
    ..These results suggest that ER-positive breast tumors could be stimulated to proliferate via a crosstalk between FXR and ER, particularly in a state of estrogen deprivation (menopause, aromatase inhibitors)...
  55. ncbi Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer
    Fatima Cardoso
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:364-9. 2004
    ..88) for Bcl-2-negative disease. Despite its being a retrospective nonrandomized study with a relatively low number of patients, our results suggest that Bcl-2 deserves further evaluation as a predictive factor of sensitivity to tamoxifen...
  56. ncbi Targeting the ubiquitin-proteasome pathway in breast cancer
    Fatima Cardoso
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:148-57. 2004
    ....
  57. ncbi Bringing molecular prognosis and prediction to the clinic
    Mariantonietta Colozza
    S C Oncologia Medica, Azienda Ospedaliera, Perugia, Italy
    Clin Breast Cancer 6:61-76. 2005
    ....
  58. ncbi Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
    Fatima Cardoso
    Translational Research Unit, Center for Education and Research in Food and Chemical Industry, Universite Libre de Bruxelles, Belgium
    Mol Cancer Ther 5:3042-51. 2006
    ....
  59. ncbi Decrease of estrogen receptor expression and associated ERE-dependent transcription in MCF-7 breast cancer cells after oligomycin treatment
    Hye Sook Seo
    Laboratoire J C Heuson de Cancérologie Mammaire, Service de Medecine Interne, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Steroids 68:257-69. 2003
    ..Hence, phosphorylations/dephosphorylations of specific sites on ER and/or co-regulators seem to govern its turnover...
  60. ncbi Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
    Rosa Giuliani
    Translational Research Unit, Jules Bordet Institute, 125, boulevard de Waterloo, 1000 Brussels, Belgium
    Eur J Cancer 43:725-35. 2007
    ....
  61. ncbi Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
    ..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
  62. doi Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, B 1000 Brussels, Belgium
    Crit Rev Oncol Hematol 77:20-9. 2011
    ....
  63. ncbi The evolution of treatment strategies: aiming at the target
    Phuong Dinh
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre De Bruxelles U L B, 121 Blvd de Waterloo, 1000 Brussels, Belgium
    Breast 16:S10-6. 2007
    ..This paper will review this evolution of treatment strategies, from the lessons learnt from the past, to the exciting promise of tailored therapy of the future...
  64. doi [Has the time arrived for gene expression use at the bedside?]
    Véronique D'Hondt
    Service de Medecine Interne, Clinique d oncologie médicale, Institut Jules Bordet, 121, boulevard de Waterloo Bruxelles 1000, Belgique
    Bull Cancer 95:336-43. 2008
    ..Here we describe the state of the art of gene expression profiling for breast cancer, and we discuss the potential impact on breast cancer patient management considering its limits and promises...
  65. ncbi The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Eur J Cancer 44:84-91. 2008
    ..To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone...
  66. ncbi Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002
    Angelo Di Leo
    Department of Chemotherapy, Jules Bordet Institute, Brussels, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Int J Clin Oncol 7:245-53. 2002
    ..In the last part of the article, the most important findings have been summarized and future avenues of research have been outlined...
  67. pmc Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays
    Christos Sotiriou
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Gaithersburg, Maryland, USA
    J Mol Diagn 4:30-6. 2002
    ..Pooling the core biopsies did not improve the concordance with excisional biopsies. In conclusion, our results suggest that core biopsies can be used as a suitable and reliable material for the determination of tumor genetic profiles...
  68. ncbi Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers
    S Loi
    Institut Jules Bordet, Brussels, Belgium M D Anderson Cancer Center, Houston, TX Institute for Cancer Research and Treatment, Torino, Italy Guy s Hospital, London, United Kingdom Peter MacCallum Cancer Center, Melbourne, Australia
    J Clin Oncol 27:533. 2009
    ..Our aim was to characterize the molecular and clinical outcome effects of PIK3CA mutations in breast cancer (BC)...
  69. ncbi Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxoru
    S Loi
    Jules Bordet Institute, Brussels, Belgium Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium IDDI, Louvain la Neuve, Belgium Institut Jules Bordet, Brussels, Belgium Breast European Adjuvant Studies Team, Jules Bordet Institute, Brussels, Belgium IBCSG Central Pathology Office, Milan, Italy Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle, Australia Irish Clinical Oncology Research Group and Molecular Therapeutics for Cancer, Dublin, Ireland Swedish Oncology Group, Stockholdm, Sweden Clinica Las Condes, Santiago, Chile Department of Oncology, Rigshospitalet, Copenhagen, Denmark Grupo Espanol de Investigacion en Cancer de Mama, Madrid, Spain Medical University of Vienna, Vienna, Austria Division of Pathology, European Institute of Oncology, Milan, Italy Sandro Pitigliani Medical Oncology Unit, Prato, Italy
    J Clin Oncol 29:556. 2011
    ..We hypothesized that TILs would be associated with prognosis and would predict increased benefit from A-based over A-T CT regimens in the triple negative (TN) and HER2+BC...
  70. doi Characterization of human breast cancer tissues by infrared imaging
    M Verdonck
    Laboratory of Structure and Function of Biological Membranes, Center of Structural Biology and Bioinformatics, Universite Libre de Bruxelles, Brussels, Belgium
    Analyst 141:606-19. 2016
    ....
  71. doi Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse
    D Fumagalli
    Jules Bordet Institute, Translational Research Unit, Universite Libre de Bruxelles, Bruxelles, Belgium
    Ann Oncol 21:vii103-6. 2010
    ..It is prospected that the greater accuracy of this new wave of predictors will provide substantial support to the existing decision tools and will significantly ameliorate our current ability to define breast cancer prognosis...
  72. doi Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial
    E de Azambuja
    Breast Unit, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:2985-9. 2013
    ..Brain metastases (BMs) pose a clinical challenge in breast cancer (BC). Lapatinib or temozolomide showed activity in BM. Our study assessed the combination of both drugs as treatment for patients with HER2-positive BC and BM...
  73. doi Change in the microenvironment of breast cancer studied by FTIR imaging
    S Kumar
    Laboratory for the Structure and Function of Biological Membranes, Center for Structural Biology and Bioinformatics, Universite Libre de Bruxelles, Campus Plaine CP 206 2 Bâtiment BC, Blvd du Triomphe, B 1050 Bruxelles, Belgium
    Analyst 138:4058-65. 2013
    ..This chemical imaging approach to analyze the breast cancer microenvironment could be used in the future for improving diagnostics of breast cancer...
  74. doi Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding
    M Verdonck
    Laboratory for the Structure and Function of Biological Membranes, Center for Structural Biology and Bioinformatics, Universite Libre de Bruxelles, Campus Plaine, Bld du Triomphe 2, CP206 2, B1050 Brussels, Belgium
    Analyst 138:4083-91. 2013
    ..This last result paves the way towards identification and characterization of cellular subtypes on FFPE tissue sections by FTIR imaging, indicating that this analysis technique could become a potential useful tool in cancer research...
  75. doi Understanding the molecular basis of histologic grade
    M Ignatiadis
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Pathobiology 75:104-11. 2008
    ..In this same meta-analysis, proliferation was shown to be the common driving force responsible for the performance of various breast cancer prognostic signatures...
  76. ncbi Gene expression profiling in breast cancer
    C Sotiriou
    Instituet Jules Bordet, Medical Oncology Clinic, Brussels, Belgium
    Ann Oncol 17:x259-62. 2006
  77. ncbi Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma
    Amir A Jazaeri
    Center for Cancer Research of the National Cancer Institute, Gaithersburg, Maryland, USA
    Mol Carcinog 36:53-9. 2003
    ..Dysregulation of centrosome function is one potential mechanistic link between genetic/epigenetic changes and the poorly differentiated phenotype in ovarian cancer...
  78. pmc Breast cancer classification and prognosis based on gene expression profiles from a population-based study
    Christos Sotiriou
    Division of Clinical Sciences, National Cancer Institute, Advanced Technology Center, 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
    Proc Natl Acad Sci U S A 100:10393-8. 2003
    ..When taken together with other array studies, our results highlight the consistent biological and clinical associations with gene expression profiles...
  79. doi Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways
    Marie Ravoet
    Molecular Immunology Unit, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Blood 114:2969-83. 2009
    ....
  80. ncbi Proliferation: the most prominent predictor of clinical outcome in breast cancer
    Christine Desmedt
    Functional Genomics and Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Cell Cycle 5:2198-202. 2006
    ..Importantly, their weight seems to be far more important in ER-positive than in ER-negative disease...
  81. ncbi Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients
    Christine Desmedt
    Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Int J Cancer 119:2539-45. 2006
    ....
  82. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  83. ncbi Breast cancer gene expression profiling: clinical trial and practice implications
    Sherene Loi
    Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Pharmacogenomics 6:49-58. 2005
    ..This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care...
  84. ncbi Circulating tumor cells (CTCs) monitoring in HER2-negative early breast cancer: Implications for secondary anti-HER2 adjuvant treatment strategies
    M Ignatiadis
    Functional Genom Translational Research Unit, Jules Bordet Institute, Brussels, Belgium Lab of Tum Cell Biol, School of Medicine, University of Crete, Heraklion, Greece Department of Medical Oncology, University General Hospital, Heraklion, Greece Department of Pathology, Heraklion, Greece Lab of Analytical Chemistry, University of Athens, Athens, Greece International Drug Development Institute, Brussels, Belgium
    J Clin Oncol 26:11502. 2008
    ..11502 Background: We have shown that the detection of peripheral blood CK19mRNA+ and HER2mRNA+ cells predicts poor outcome in early breast cancer and that trastuzumab can effectively eliminate these cells...
  85. doi Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers
    D Fumagalli
    Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Free University of Bruxelles, Brussels, Belgium
    Ann Oncol 27:1860-6. 2016
    ..The molecular landscape of ER+ relapsed disease is not well characterized. In this study, we aimed to describe the genomic evolution between primary (P) and matched metastatic (M) ER+ BCs after failure of adjuvant therapy...
  86. doi Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients
    S De Brakeleer
    Laboratory of Molecular and Medical Oncology, Vrije Universiteit Brussel, Brussels, Belgium
    Clin Genet 89:336-40. 2016
    ..These patients should become eligible for exploring the efficacy of poly (ADP-ribose) polymerase (PARP) inhibitors. ..
  87. doi Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer
    F Rothe
    Breast Cancer Translational Research Laboratory J C Heuson, Universite Libre de Bruxelles, Institut Jules Bordet, Brussels
    Ann Oncol 25:1959-65. 2014
    ..Molecular screening programs use next-generation sequencing (NGS) of cancer gene panels to analyze metastatic biopsies. We interrogated whether plasma could be used as an alternative to metastatic biopsies...
  88. ncbi Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
    Christos Sotiriou
    Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    Nat Rev Cancer 7:545-53. 2007
    ..We also discuss the potential of molecular signatures to have an impact on individual breast cancer patient management, and ultimately to accelerate the transition between empirical and tailored medicine...
  89. ncbi Correlations of estrogen receptor (ER) related genomic transcription and ER gene expression with increasing AJCC stage of ER-positive breast cancer
    E Andreopoulou
    M D Anderson Cancer Center, Houston, TX Nuvera Biosciences, Inc, Woburn, MA Institut Jules Bordet, Brussels, Belgium
    J Clin Oncol 27:1044. 2009
    ..We investigated whether expression of genes for receptors ER (ESR1), progesterone receptor (PGR), or HER-2 (ERBB2), the SET index, or a housekeeper gene (GAPDH) vary by stage of ER-positive breast cancer...
  90. ncbi Genomic grade: Feasibility in routine practice and influence on treatment decision in early breast cancer
    O Metzger
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Ipsogen, Marseille, France Jules Bordet Institute, Brussels, Belgium IDDI, Louvain la Neuve, Belgium Grand Hôpital de Charleroi, Charleroi, Belgium Clinique Saint Vincent, Liege, Belgium Jules Bordet Institute, Bruxelles, Belgium CHU Ambroise Pare, Mons, Belgium CHU Ambroise Pare, CHU Tivoli, Mons, Belgium CHU Tivoli, La Louviere, Belgium Clinique et Maternité Sante Elisabeth, Namur, Belgium RHMS Clinique Louis Caty, Baudour, Belgium
    J Clin Oncol 29:606. 2011
    ..Secondary objectives include GGI classification performance and impact on treatment recommendations...
  91. doi The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
    R Salgado
    Breast Cancer Translational Research Laboratory Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium
    Ann Oncol 26:259-71. 2015
    ..TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC...
  92. ncbi Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer
    F Cardoso
    Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, 1000 Brussels, Belgium
    Int J Oncol 24:201-9. 2004
    ..Topo-II protein was overexpressed in 6/11 (55%) CR and in 2/17 (12%) PD to anthracyclines, while in the control group, overexpression was seen in 5/7 (71%) CR and 8/20 (40%) PD...
  93. ncbi Understanding the biology of triple-negative breast cancer
    C Criscitiello
    Breast Cancer Translational Research Laboratory J C Heuson, Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium
    Ann Oncol 23:vi13-8. 2012
    ..It is anticipated that a greater understanding of the biology of TNBC and its complex heterogeneity will reveal novel targets or identify markers around which clinical trials in molecularly well-defined sub-groups can be designed...
  94. ncbi HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation
    H Akl
    Laboratory of Experimental Hematology, Bordet Institute, Faculty of Medicine, Universite Libre de Bruxelles, Brussels, Belgium
    Leukemia 21:788-96. 2007
    ..This could be a major event in the process of the malignant transformation into ATLL...
  95. ncbi Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
    Lissandra Dal Lago
    Translational Research Unit, Bordet Institute, Brussels, Belgium
    Mol Cancer Ther 5:2572-9. 2006
    ..This project aimed to determine the optimal scoring method for fluorescence in situ hybridization (FISH) assay...
  96. ncbi Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice
    Yan Ma
    Pathology Department, Institut Jules Bordet, Brussels, Belgium
    Clin Cancer Res 11:4393-9. 2005
    ..To assess the effect of chromosome 17 copy number on HER-2/neu status determination in breast cancers...
  97. ncbi Challenges in breast cancer clinical trial design in the postgenomic era
    Sherene Loi
    Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Curr Opin Oncol 16:536-41. 2004
    ..The neoadjuvant setting presents a unique opportunity to test new concepts in a previously untreated patient population, because they may yield preliminary answers in a shorter time than that required in adjuvant trials...
  98. ncbi New tools for assessing breast cancer recurrence
    Phuong Dinh
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Res 141:99-118. 2008
  99. doi Circulating tumor cells and emerging blood biomarkers in breast cancer
    Carmen Criscitiello
    Medical Oncology Department, Jules Bordet Institute, Brussels, Belgium
    Curr Opin Oncol 22:552-8. 2010
    ..To critically review the latest findings concerning the role of circulating tumor cells (CTCs) and other blood biomarkers in breast cancer...
  100. ncbi Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation
    Phillipe Lothaire
    Department of Surgery, Institut Jules Bordet, Brussels, Belgium
    Head Neck 28:256-69. 2006
    ..The aim of this article is to review recent developments in the biological understanding of head and neck squamous cell carcinomas...
  101. pmc Defining the galaxy of gene expression in breast cancer
    Edison T Liu
    Genome Institute of Singapore, 1 Science Park Road, 05 01 Science Park II, Singapore
    Breast Cancer Res 4:141-4. 2002
    ..These principles are examined and the impact of these results on understanding the biology and the clinical behaviour of breast tumors is explored...